Global Sponsored by
Only on SkinInc.com: Exclusive commentary from Silvia Schweickart, brand manager, Filler & Toxin Portfolio, for Merz Pharmaceuticals GmbH, is included in this news item explaining what women want in regard to beauty, providing valuable insight for your medical esthetics practice.
At the 22nd World Congress of Dermatology in Seoul, Korea, Merz Aesthetics celebrated its commitment to the Asian market and reinforced its plans to become a global leader in the aesthetics business with the release of the third chapter of its “Face Value” Beauty Survey.
Currently, Merz Aesthetics operates in 16 countries around the globe with a primary presence in America and Europe. The Asia Pacific Region is quickly becoming one of the most exciting and dynamic aesthetics markets in the world and represents a strategic opportunity for Merz. The company recently announced it will build its regional headquarters in Singapore and has committed to providing clinical training, technical workshops and scientific background to physicians across the region. Most recently in addition to the Singapore office, Merz has established offices in Korea and Taiwan.
The Asia-Pacific facial injectable market—comprised of botulinum toxin, hyaluronic acid dermal fillers, particle and polymer fillers and collagen fillers—is expected to grow through 2014 due to increased physician adoption of profitable facial injectable treatments in their practices and growing patient demand for less invasive cosmetic procedures. This consumer demand backed by physician innovation, product availability and increasing consumer disposable income intersect, to create double-digit growth year upon year in the region.
“The extreme growth of the minimally invasive facial injectable market in South Korea specifically and across Asia, suggests a high aesthetic consciousness in the Asia-Pacific region, which will fuel continued demand for cosmetic procedures, including facial injectable treatments,” says Kyle Seo, MD, PhD, director of Modelo Clinic, Seoul, South Korea. “The large pool of patients in this region represents a significant opportunity for revenue potential in the facial injectable market.”